Biocon gets Health Canada approval for Yesintek Autoinjector Pen

Regulatory product approvalBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹433.65

prior close

₹434.95

announcement price

After-mkt

timing

Nifty Midcap 150market+0.8%-1.4% vs market

Pharmaceuticals peers, median of 160sector+0.8%-1.4% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Midcap 150 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.5

15m

-0.6

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5+0.8-1.4+0.8-1.4

Next day

-1.8+0.4-2.2+0.0-1.8

-1.8+0.9-2.7+0.1-1.8

-1.5+2.1-3.7+0.6-2.2

-1.9+1.8-3.7+1.0-2.9

-1.9+2.1-4.0+0.6-2.6

-1.6+1.9-3.5+1.6-3.2

15d

-4.8+1.6-6.5+0.5-5.3

-5.0+2.6-7.6+2.1-7.1

-13.1-4.7-8.4+4.2-17.3

-18.9-7.4-11.5-1.9-17.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's Canada subsidiary received Health Canada approval for Yesintek (ustekinumab) Autoinjector Pen in 45 mg and 90 mg formats. Yesintek treats plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Health Canada had earlier approved the prefilled syringe and IV versions in October 2025. The autoinjector offers a format not available from the originator product in Canada, expanding Biocon's immunology portfolio in that market.

Likely market impact

Strengthens Biocon's immunology portfolio in Canada with a differentiated delivery format, supporting biosimilar revenue growth.